Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Inclusion Criteria:

• Signed informed consent

• On study drug at PANORAMA-HF Part 2 EOS visit. Does not have any significant safetyissue

Exclusion Criteria:

• Subject only participated in PANORAMA-HF Part 1 or was a SF in PANORAMA-HF orpermanently discontinued study drug in PANORMA-HF Part 2

• Use of investigational drugs within 5 half-lives of enrollment or within 30 days (longer duration); with the exception of PANORAMA-HF study drug (requires >/=36-hourwashout before baseline visit)

• History of hypersensitivity or allergy to study treatment, its excipients or drugsof similar chemical class, ACEIs, ARBs, or NEP inhibitor and known/suspectedcontraindications to sacubitril/valsartan

• Renal vascular hypertension (including renal artery stenosis)

• Significant renal estimated glomerular filtration rate disorder (eGFR calculatedusing modified Schwartz formula <30% mean GFR for age); hepatic disorder (serumaspartate aminotransferase or alanine aminotransferase > 3 times upper limit ofnormal); gastrointestinal disorder or biliary disorder

• History of angioedema

• Parents or legal guardians of subject who do not give consent or allow the child togive assent, or inability of patient or parents/legal guardians to followinstructions or comply with follow-up procedures

• Any medical condition(s) that may put the patient at risk in the investigator'sopinion or that the investigator deems unsuitable for the study

• Other protocol defined inclusion/exclusion criteria may apply